<DOC>
	<DOCNO>NCT01249664</DOCNO>
	<brief_summary>VEGF Trap-Eye test safety efficacy patient vision loss due choroidal neovascularization secondary pathologic myopia . This placebo-controlled trial . 3 4 patient receive injection VEGF Trap-Eye affect eye ( repeated injection require ) , 1 4 patient receive sham injection require needle stick , make patient unaware whether received active treatment . Outcome two treatment group compare 24 week . From week 24 , sham patient may receive active treatment . Total duration study 48 week .</brief_summary>
	<brief_title>VEGF Trap-Eye Choroidal Neovascularization Secondary Pathologic Myopia ( mCNV )</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<criteria>Able read ( , unable read due visual impairment , read verbatim person administer informed consent form family member ) understand inform consent form willing sign inform consent form Signed informed consent form . In Japan , inform consent form subject age 20 year require cosignature subject 's legally authorize representative . Men woman ≥ 18 year age Myopia great equal 6 D OR axial length great equal 26.5 mm Active subfoveal juxtafoveal ( within 1 199 μm center fovea ) CNV secondary pathologic myopia define leakage FA Bestcorrected visual acuity 73 35 letter ( ETDRS equivalent 20/40 20/200 ) study eye 4 meter Decrease vision study eye determine investigator , use his/her medical judgment , primarily result current active mCNV Willing , commit , able return clinic visit complete studyrelated procedure Only one functional eye Ocular medium insufficient quality obtain fundus OCT image study eye Greatest linear dimension ( GLD ) lesion study eye great 12 disc area Recurrent mCNV study eye Aphakia study eye History presence CNV origin pathologic myopia study eye Ocular inflammation external ocular inflammation study eye Concurrent disease study eye would compromise BCVA require medical surgical intervention study period Any ocular disorder study eye , opinion investigator , may confound interpretation study result Significant scar atrophy fovea indicate substantial irreversible vision loss study eye History idiopathic autoimmuneassociated uveitis either eye Evidence examination infectious blepharitis , keratitis , scleritis , conjunctivitis either eye current treatment serious systemic infection Vitreomacular traction traction retinal detachment , epiretinal membrane either eye Any iris neovascularization and/or vitreous hemorrhage either eye Uncontrolled glaucoma , previous filtration surgery either eye Prior concomitant treatment In study eye : Any prior concomitant treatment another investigational agent mCNV Any previous panretinal photocoagulation subfoveal thermal laser therapy Any prior treatment photodynamic therapy Cataract surgery within 3 month prior Day 1 Yttriumaluminumgarnet laser capsulotomy within 2 month prior Day 1 Any intraocular surgery within 3 month prior Day 1 History vitreoretinal surgery and/or scleral buckle surgery Any prior treatment antiVEGF agent Previous use intraocular periocular corticosteroid either eye within 3 month prior Day 1 Previous assignment treatment study Uncontrolled hypertension History cerebrovascular disease myocardial infarction within 6 month prior Baseline/Day 1 History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , may affect interpretation result study , render subject high risk treatment complication Women childbearing potential without contraception , woman intend breastfeed study . All subject ( men woman ) childbearing potential unwilling use adequate birth control measure course study . Renal failure require dialysis renal transplant Participation investigational study within 30 day prior Screening/Visit 1 involved treatment drug ( exclude vitamin mineral ) device Known serious allergy fluorescein sodium injection angiography Verteporfin Inability obtain fundus photograph fluorescein angiograms sufficient quality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>sham-controlled</keyword>
	<keyword>pathologic myopia</keyword>
	<keyword>mCNV</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>vision loss</keyword>
	<keyword>macular damage</keyword>
</DOC>